Laidlaw initiated coverage of Senti Bio (SNTI) with a Buy rating and $5 price target Senti is an early clinical stage oncology-emphasized biotech company that focuses on a novel and differentiated CAR-NK therapy, SENTI-202, as a potential high-risk relapsed or refractory acute myeloid leukemia treatment, the analyst tells investors in a research note. The firm says the company recently reported “very promising” Phase I interim results.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNTI: